Article Text

Download PDFPDF
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes
  1. H von Bibra1,
  2. A Hansen1,
  3. V Dounis1,
  4. T Bystedt2,
  5. K Malmberg1,
  6. L Rydén1
  1. 1Department of Cardiology, Karolinska Hospital, Stockholm, Sweden
  2. 2Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden
  1. Correspondence to:
    Professor Helene von Bibra
    Department of Endocrinology, Academic Hospital München-Bogenhausen, Englschalkingerstrasse 77, 81925 Munich, Germany;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Diastolic dysfunction and compromised myocardial blood flow are characteristic findings in patients with non-insulin dependent diabetes. We conducted a pilot trial to test the hypothesis that intensified metabolic control would improve myocardial function and perfusion in patients with non-insulin dependent diabetes.


Twenty five patients with non-insulin dependent diabetes (19 men, mean age 60 (9) years, diabetes duration 8 (7) years) were subjected to intensified metabolic control based on an increased dose of insulin (group A: n  =  16, fasting β glucose 11 (4) mmol/l) or of oral treatment (group B: n  =  9, fasting β glucose 11 (3) mmol/l). Exclusion criteria were a moderate to severe degree of diabetic microvascular complications, clinical signs of heart failure, valvar disease, severe hypertension, and concomitant hepatic or renal dysfunction. A further eight patients were studied as controls during unchanged medication (mean age 62 (6) years, fasting β glucose 8 (2) mmol/l).

Evidence of coronary artery disease was assessed based on coronary angiography or stress echocardiograms (dobutamine 10–40 mg/kg/min). All patients were trained to measure blood glucose with a reflectometer (Accutrend Sensor, Roche Diagnostics, Stockholm, Sweden). Self reported concentrations of fasting blood glucose averaged from three days before each visit served as a reference for glucose control. Myocardial perfusion and function were assessed by ultrasound technology at rest and during maximum vasodilatation (dipyridamole 0.84 mg/kg) before (visit 1) and three weeks after (visit 2) …

View Full Text